Table 1

Baseline characteristics of chronic obstructive pulmonary disease (COPD) patients taking fluticasone propionate (FP) and/or salmeterol and reference patients

FP and salmeterolFP aloneSalmeterol aloneReference
Patients n3174312973620
Female %52.7*52.7*49.2*44.2
Age at diagnosis yrs#64.6±8.5*66.1±8.8*68.6±9.2*72.2±9.8
Smoking status %
 Non or exsmoker35.0*32.5*33.7*26.9
 Unknown6.9*7.0*12.5*20.7
 Current smoker58.060.6*53.952.4
Daily cigarette consumption packs#0.69±0.390.73±0.500.67±0.410.71±0.46
Severe COPD %6.6*5.18.4*3.8
Baseline+ treatment
Inhaled corticosteroids %89.3*66.4*39.7*4.4
Inhaled β2-agonists %89.3*71.0*65.0*33.1
 SABA73.8*67.3*51.5*31.3
 LABA65.6*9.0*23.9*0.4
Other adrenergic stimulants %2.81.24.4*2.4
Oral β2-agonists %7.67.26.18.6
Xanthines %16.7*14.213.110.8
Anticholinergics %26.2*23.0*24.6*5.8
Oral corticosteroids %58.7*57.8*37.4*16.8
Combined bronchodilator products %7.3*5.3*5.4*1.8
Oxygen therapy %2.82.84.03.1
Nebulised therapy %4.1*2.3*5.1*0.9
Baseline+ use of health services
COPD-related GP visits %64.067.765.368.7
COPD-related hospitalisation§ %7.96.75.46.2
COPD-related A&E visits %1.6*0.00.00.1
History of comorbid conditionsƒ
Comorbid conditions present %23.0*31.1*31.3*43.3
  • SABA: short-acting β2-agonists

  • LABA: long-acting β2-agonists

  • GP: general practitioner

  • A&E: accident and emergency

  • #: mean±sd

  • : as defined in 14

  • +: 6 months before start of regular treatment

  • §: in- and outpatient

  • ƒ: as defined in 16

  • *: p<0.05 versus reference group